Molecular pathways of urothelial development and bladder tumorigenesis.

[1]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[2]  R. Ackermann,et al.  "Cancer stem cells"-lessons from Hercules to fight the Hydra. , 2008, Urologic oncology.

[3]  R. Montironi,et al.  Loss of heterozygosity at 9q32–33 (DBC1 locus) in primary non‐invasive papillary urothelial neoplasm of low malignant potential and low‐grade urothelial carcinoma of the bladder and their associated normal urothelium , 2008, The Journal of pathology.

[4]  R. Moll,et al.  The human keratins: biology and pathology , 2008, Histochemistry and Cell Biology.

[5]  E. Fuchs,et al.  More than one way to skin . . . , 2008, Genes & development.

[6]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[7]  C. Cordon-Cardo.  Molecular alterations associated with bladder cancer initiation and progression , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[8]  Peter A. Jones,et al.  p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Dinney,et al.  Targeted therapies in bladder cancer--an update. , 2007, Urologic oncology.

[10]  A. Fierabracci,et al.  Identification and characterization of adult stem/progenitor cells in the human bladder (bladder spheroids): perspectives of application in pediatric surgery , 2007, Pediatric Surgery International.

[11]  R. Isseroff,et al.  Urothelial progenitor cells: regional differences in the rat bladder , 2007, Cell proliferation.

[12]  C. Cordon-Cardo,et al.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. , 2007, The Journal of clinical investigation.

[13]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[14]  T. Mak,et al.  Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. , 2006, Cancer research.

[15]  N. Malats,et al.  Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Aldape,et al.  Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy , 2006, Clinical Cancer Research.

[17]  N. Malats,et al.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. , 2006, Cancer research.

[18]  H. Pickett,et al.  DBC1 re-expression alters the expression of multiple components of the plasminogen pathway , 2006, Oncogene.

[19]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[20]  Victor E. Reuter.  The pathology of bladder cancer. , 2006, Urology.

[21]  Carsten Wiuf,et al.  Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors , 2005, Clinical Cancer Research.

[22]  Adel H Jebar,et al.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.

[23]  N. Mitra,et al.  A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data. , 2005, Health economics.

[24]  S. Santa Cruz,et al.  Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[26]  M. Crundwell.  Pathology and genetics of tumours of the urinary system and male genital organs , 2004 .

[27]  W. Gerald,et al.  Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control , 2004, Nature.

[28]  R. Millikan,et al.  Focus on bladder cancer. , 2004, Cancer cell.

[29]  Peter A. Jones,et al.  Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer , 2004, The Journal of pathology.

[30]  T. Sun,et al.  p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis , 2004, Oncogene.

[31]  Davies Br.  Gene products involved in metastasis of bladder cancer. , 2003 .

[32]  R. Bryan,et al.  ‘Superficial’ bladder cancer – time to uncouple pT1 tumours from pTa tumours , 2002, BJU international.

[33]  C. Cordon-Cardo,et al.  Loss of p63 expression is associated with tumor progression in bladder cancer. , 2002, The American journal of pathology.

[34]  T. Sun,et al.  Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. , 2002, Cancer research.

[35]  C. Cordon-Cardo,et al.  p63 expression profiles in human normal and tumor tissues. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  T. Sun,et al.  Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation , 2001, Oncogene.

[37]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.

[38]  T. Sun,et al.  Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. , 1999, Cancer research.

[39]  François G. Meyer,et al.  Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. , 1999, The American journal of pathology.

[40]  J. Cheville,et al.  Survival of patients with carcinoma in situ of the urinary bladder , 1999, Cancer.

[41]  H. Maartmann-Moe,et al.  The long‐term outcome in patients with superficial transitional cell carcinoma of the bladder: a single‐institutional experience , 1999, BJU international.

[42]  M. Knowles,et al.  Mutation of the 9q34 gene TSC1 in sporadic bladder cancer , 1999, Oncogene.

[43]  J. Tomaszewski,et al.  PTCH gene mutations in invasive transitional cell carcinoma of the bladder , 1998, Oncogene.

[44]  Patricia A. Elder,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1998, Genomics.

[45]  J. Eble,et al.  Carcinoma of the urinary bladder: a review of its diverse morphology. , 1997, Seminars in diagnostic pathology.

[46]  C. Cordon-Cardo,et al.  Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. , 1997, Cancer research.

[47]  J. Southgate,et al.  Cytokeratin 20 as an objective marker of urothelial dysplasia. , 1996, British journal of urology.

[48]  T. Sun,et al.  Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. , 1994, The Journal of biological chemistry.

[49]  C. Cordon-Cardo,et al.  p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns , 1994, International journal of cancer.

[50]  P. Swanson,et al.  Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. , 1994, American journal of clinical pathology.

[51]  C. Cordon-Cardo,et al.  Genetic alterations in bladder cancer , 1993, The Lancet.

[52]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[53]  B. Czerniak,et al.  Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. , 1992, Human pathology.

[54]  C. Cordon-Cardo,et al.  Expression of blood group antigens in bladder cancer: current concepts. , 1992, Seminars in surgical oncology.

[55]  C. Cordon-Cardo,et al.  Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. , 1992, Journal of the National Cancer Institute.

[56]  M. Barbacid,et al.  Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11 , 1982, Nature.

[57]  E. Zwarthoff,et al.  Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. , 2008, Neoplasia.

[58]  Scott H. Kurtzman,et al.  AJCC cancer staging atlas , 2006 .

[59]  D. Theodorescu.  Molecular pathogenesis of urothelial bladder cancer. , 2003, Histology and histopathology.

[60]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[61]  D. Chopin,et al.  Short Communication Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors , 2001 .